Bristol Myers Squibb Sees Eliquis Revenue Rising 20%-25% in 2026
Bristol Myers Squibb still expects total worldwide Eliquis revenue to increase 20%-25% in 2026 versus a year earlier.
Related stories
Shionogi Revises 2026/27 Group Operating Forecast
Shionogi raised its 2026/27 group operating profit forecast by 4.5%.
M impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC
Yokorei Revises 2025/26 Parent Recurring Profit Forecast
Yokorei revised its 2025/26 parent recurring profit forecast.
L impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC
Yokorei Revises 2025/26 Parent Net Forecast to Loss
Yokorei revised its 2025/26 parent net forecast from profit to loss.
M impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC
Yokorei Cuts Standalone Ordinary Profit Forecast
Yokorei lowered its standalone ordinary profit forecast by 1.7% from the previous forecast.
L impact | EARNINGS | Oct 30, 2026, 01:00 AM UTC
Hyundai Mobis 3Q Net Profit Falls Below FactSet Consensus
M impact | EARNINGS | Oct 30, 2026, 12:58 AM UTC
Carbonxt Group Reports A$3.3 Million September-Quarter Revenue
M impact | EARNINGS | Oct 30, 2026, 12:58 AM UTC